Amyvid & Alzheimers Lesson: FDA Approval Is Not A Coverage Guarantee
Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…